Glepaglutide for short bowel syndrome
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a new medication called glepaglutide to see if it can help people with short bowel syndrome (SBS) who need IV nutrition or fluids at least 3 days a week. The goal is to reduce or even stop the need for these IV treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 90 years old.
- You must have short bowel syndrome with your remaining small intestine being less than 200 cm (about 79 inches) long.
- You need IV nutrition or fluids (called parenteral support) at least 3 days a week.
- You must have a stoma (a bag on your belly for waste) or still have your colon connected to your small intestine.
- You cannot have had more than 2 hospital stays related to SBS or parenteral support in the last 6 months.
- You cannot have active cancer (except for some skin cancers) within the last 5 years, and you must not have a body mass index (BMI) below 18.5.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether sonefpeglutide is safe and how the body handles it (pharmacokinetics) in people with short bowel syndrome. It may help people who still need nutrition through a tube because their intestinal condition is stable.
This study tests a medicine called teduglutide for adults in China with short bowel syndrome who need long-term IV nutrition or fluids (parenteral support). The goal is to see if teduglutide can help them reduce or stop the need for these IV treatments.
This trial tests a new medicine called PJ009 for people with short bowel syndrome who need intravenous (IV) nutrition support. It aims to help reduce the need for IV nutrition. To join, you must have been dependent on IV nutrition for at least six months and be on a stable schedule.
This trial tests if crofelemer can reduce diarrhea and fluid loss in people with short bowel syndrome who have a stoma (no colon connection) and need intravenous nutrition or fluids. The goal is to see if it improves gut function and quality of life.
This study tests a new treatment called FT1 for people with short bowel syndrome. It aims to help you absorb more nutrients and fluids from food, potentially reducing the need for IV nutrition.
This trial studies whether the Eclipse XL1 system is safe and may help people with short bowel syndrome, in both children and adults. It will check how well the approach works and watch for side effects over the study period.
Hear when a new Short Bowel Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.